A Study of TAK-071 in People With Parkinson Disease
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Ef ...
Parkinson Disease;Healthy Participants
Drug: TAK-071;Drug: Placebo
Takeda
Michael J. Fox Foundation for Parkinson's Research